Literature DB >> 9621086

Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids.

F Längle-Rouault1, V Patzel, A Benavente, M Taillez, N Silvestre, A Bompard, G Sczakiel, E Jacobs, K Rittner.   

Abstract

A 100-fold increase in luciferase activity was observed in 293 cells, stably expressing Epstein-Barr nuclear antigen 1 (EBNA1; 293-EBNA1 cells), that had been transiently transfected with plasmids carrying Epstein-Barr virus (EBV) oriP sequences. This increase was observed in comparison to reporter gene activity obtained after transfection with a plasmid carrying no oriP sequences. The luciferase gene on these plasmids was under the control of either the cytomegalovirus immediate-early 1 gene enhancer-promoter (CMV IE1) or the Rous sarcoma virus promoter. The increase of reporter gene activity was not due to plasmid replication, since a similar enhancement was observed in the presence of aphidicolin, an inhibitor of replicative DNA synthesis, or after deletion of the dyad symmetry (DS) element within oriP. Luciferase production was not increased in the presence of only the DS element. Microinjection of plasmids carrying the CMV IE1 promoter-driven luciferase gene with or without oriP sequences into the nuclei of 293-EBNA1 cells resulted in a 17-fold increase in luciferase activity. Cytoplasmic injection of these plasmids led to an enhancement of luciferase activity of up to 100-fold. This difference in the factor of activation after nuclear or cytoplasmic injection could be ascribed to increased transport of plasmids carrying oriP from the cytoplasm to the nucleus in the presence of EBNA1. These data suggest the possibility of substantially increasing the apparent expression of a gene under the control of a strong constitutive promoter in the presence of oriP sequences and EBNA1. This improvement in expression is due to intranuclear enhancement of gene expression. oriP-specific transport of plasmid DNA from the cytoplasm of 293-EBNA1 cells to the nucleus seems to contribute to the observed effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621086      PMCID: PMC110430     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Functional domains of Epstein-Barr virus nuclear antigen EBNA-1.

Authors:  R F Ambinder; M A Mullen; Y N Chang; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

2.  Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA.

Authors:  R F Ambinder; W A Shah; D R Rawlins; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.

Authors:  M T Puglielli; M Woisetschlaeger; S H Speck
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus.

Authors:  D A Wysokenski; J L Yates
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

5.  Plasmid DNA entry into postmitotic nuclei of primary rat myotubes.

Authors:  M E Dowty; P Williams; G Zhang; J E Hagstrom; J A Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 6.  Nucleocytoplasmic transport.

Authors:  D Görlich; I W Mattaj
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

7.  An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene.

Authors:  T A Gahn; B Sugden
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

8.  Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice.

Authors:  J B Wilson; J L Bell; A J Levine
Journal:  EMBO J       Date:  1996-06-17       Impact factor: 11.598

9.  Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin alpha2.

Authors:  N Fischer; E Kremmer; G Lautscham; N Mueller-Lantzsch; F A Grässer
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

10.  Cellular and molecular barriers to gene transfer by a cationic lipid.

Authors:  J Zabner; A J Fasbender; T Moninger; K A Poellinger; M J Welsh
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

View more
  42 in total

1.  Sequence requirements for plasmid nuclear import.

Authors:  D A Dean; B S Dean; S Muller; L C Smith
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

2.  Nuclear import of plasmid DNA in digitonin-permeabilized cells requires both cytoplasmic factors and specific DNA sequences.

Authors:  G L Wilson; B S Dean; G Wang; D A Dean
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

3.  Cell-specific nuclear import of plasmid DNA.

Authors:  J Vacik; B S Dean; W E Zimmer; D A Dean
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

4.  Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus.

Authors:  D F Ceccarelli; L Frappier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1.

Authors:  Hong Wu; Priya Kapoor; Lori Frappier
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  The cis-acting family of repeats can inhibit as well as stimulate establishment of an oriP replicon.

Authors:  E R Leight; B Sugden; E R Light
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Promoter-proximal regulatory elements involved in oriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines.

Authors:  T Nilsson; H Zetterberg; Y C Wang; L Rymo
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature.

Authors:  J L Young; J N Benoit; D A Dean
Journal:  Gene Ther       Date:  2003-08       Impact factor: 5.250

9.  Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1.

Authors:  John Sears; John Kolman; Geoffrey M Wahl; Ashok Aiyar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 10.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.